Blocking a Lipid Enzyme Rejuvenates Aging Blood Stem Cells and Extends Lifespan

As organisms age, their hematopoietic stem cells (HSCs) — the master cells that replenish all blood and immune cells — progressively decline in quality. This leads to a weakened immune system, chronic low-grade inflammation, and reduced lifespan. Despite the stakes, few therapeutic strategies exist to reverse HSC aging. This study identifies ferroptotic stress as a central driver of that decline and maps the molecular pathway responsible.

The researchers discovered that aged HSCs accumulate elevated levels of sphingosine-1-phosphate (S1P), a bioactive lipid produced by increased sphingosine metabolism. S1P then suppresses the activity of HDAC enzymes, leading to increased acetylation of histone H3 at lysine 9 (H3K9ac) — an epigenetic mark that ramps up expression of Lpcat2, an enzyme that incorporates pro-ferroptotic phospholipids into cell membranes. The result is a membrane composition that makes aged HSCs highly vulnerable to ferroptosis, a regulated form of iron-dependent lipid peroxidation cell death.

Genetic deletion or pharmacological inhibition of sphingosine kinase 2 (Sphk2) — the enzyme responsible for S1P production — reversed these changes. In both aged mouse and human HSCs, Sphk2 inhibition lowered S1P, reduced Lpcat2 expression, diminished ferroptotic lipid accumulation, and improved stem cell function. Critically, treated aged mice showed restored immune homeostasis and a modest but measurable extension of lifespan.

These findings establish an S1P-HDAC-Lpcat2 axis that bridges epigenetic reprogramming and lipid metabolism to drive HSC aging through ferroptotic stress. Sphingosine kinase 2 emerges as a promising pharmacological target for combating immune aging and potentially extending healthspan.

Key caveats: the full paper was not available; this summary is based on the abstract only. Lifespan extension in mice was described as modest, and translation to humans will require dedicated clinical investigation.